WO2018133007A1 - 一种调节人体肠胃机能的饮品 - Google Patents

一种调节人体肠胃机能的饮品 Download PDF

Info

Publication number
WO2018133007A1
WO2018133007A1 PCT/CN2017/071715 CN2017071715W WO2018133007A1 WO 2018133007 A1 WO2018133007 A1 WO 2018133007A1 CN 2017071715 W CN2017071715 W CN 2017071715W WO 2018133007 A1 WO2018133007 A1 WO 2018133007A1
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
probiotics
yeast
purified water
white sugar
Prior art date
Application number
PCT/CN2017/071715
Other languages
English (en)
French (fr)
Inventor
陈云
Original Assignee
陈云
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 陈云 filed Critical 陈云
Priority to PCT/CN2017/071715 priority Critical patent/WO2018133007A1/zh
Priority to CN201780009884.9A priority patent/CN108882730B/zh
Publication of WO2018133007A1 publication Critical patent/WO2018133007A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
    • A23L2/38—Other non-alcoholic beverages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/88—Liliopsida (monocotyledons)
    • A61K36/906—Zingiberaceae (Ginger family)
    • A61K36/9064—Amomum, e.g. round cardamom
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/14—Fungi; Culture media therefor
    • C12N1/16—Yeasts; Culture media therefor
    • C12N1/18—Baker's yeast; Brewer's yeast

Definitions

  • the invention belongs to the field of daily life drinks, and relates to a functional beverage, in particular to a beverage for regulating human gastrointestinal function containing probiotics and various amino acids.
  • the gastrointestinal tract is the most important organ for human body nutrient absorption and digestion, and it is also a common and frequently-occurring organ. Modern people have a fast pace of life, abnormal working schedule, high work pressure, unreasonable diet, irregularities, etc., which can cause gastrointestinal movement and secretion disorders. Many people have mild or severe gastrointestinal symptoms, which seriously lead to corresponding Gastrointestinal diseases are produced.
  • the object of the present invention is to provide a drink for regulating the gastrointestinal function of a human body, which organically combines a health care medicine, an amino acid and a probiotic, can effectively regulate the movement and secretion of the human stomach, and is convenient to drink and has a good effect.
  • the technical proposal of the present invention is to provide a beverage for regulating the gastrointestinal function of a human body, wherein the ginseng ingredients are pulverized and mixed with white granulated sugar and white wine, and then purified water and probiotics are added for propagation to obtain a high concentration.
  • the probiotic liquid, the high concentration probiotic liquid is added to the comprehensive amino acid for dry fermentation to obtain the amino acid material, and finally the amino acid material is purified by adding pure water, white sugar and yeast to obtain the finished product;
  • the reference ingredients include: 3-7 g chicken inner gold, 3-7 g amomum, 3-7 g malt, 3-7 g sputum, 3-7 g atractylodes, 3-7 g citrus peel, 3-7 g lentils, 3-7 g ginseng, 3 to 7 g of stone scorpion;
  • the probiotics are prepared by mixing the following percentages of bacteria: Bulgarian lactic acid bacteria 6-16%, Streptococcus thermophilus 5-17%, Lactobacillus acidophilus 7-18%, Lactobacillus plantarum 5-19%, Lactobacillus casei 8-23% and Lactobacillus 7-21%;
  • the comprehensive amino acid is prepared by mixing the following raw materials by weight: 1 to 3% of aspartic acid, 1 to 3% of threonine, 0.8 to 3% of serine, 1 to 3% of glutamic acid, and 1 to 3 of glycine.
  • 3% alanine 0.8-3%, gamma citrate 1-4%, methionine 1.4-4%, isoleucine 0.9-3%, tyrosine 1.2-4%, phenylalanine 1-3% , aminobutyric acid 0.8 to 4%, proline 1 to 4%, proline 1.4 to 4%, lysine 1.3 to 4%, proline 1 to 3%, histidine 1 to 4%, color 5 to 23% for lysine, 1 to 5% for arginine, and 8 to 25% for hydroxyproline;
  • the yeast is prepared by mixing bread yeast and Saccharomyces cerevisiae by a weight ratio of 1:1;
  • the preparation method of the above-mentioned beverage for regulating human gastrointestinal function is as follows:
  • the ginseng ingredients are separately pulverized, passed through a 100-200 mesh sieve, and sterilized by high temperature to obtain a ginseng powder;
  • the weight ratio of the reference micro powder, white sugar and white wine is: 2 to 4:2 to 8:1;
  • Concentration probiotic liquid wherein: the weight ratio of the feeding solution, purified water and probiotics is 30 to 50: 1000 to 1300:1;
  • the finished product After the finished product has passed the test, it will enter the aseptic production line for quantitative packaging, and obtain a drink that can regulate the gastrointestinal function of the human body.
  • the present invention selectively selects components of chicken, gold, amomum, malt, alfalfa, atractylodes, tangerine peel, lentils, ginseng, and sarcophagus, and combines them according to a certain ratio.
  • Ingredient ingredients, the efficacy of the drug produces synergistic effect; the chicken can eliminate the stomach and help digestion, can promote the secretion of gastric juice, improve the acidity and digestive power of the stomach, so that the gastric motility function is obviously enhanced, and the gastric emptying is accelerated.
  • Amomum villosum is scattered, aroma and dampness, the main spleen and stomach, for the dampness and spleen to take medicine; malt can improve the food, abdominal pain, spleen and less food. It is good for spleen and spleen and spleen, and it has the functions of promoting digestion, protecting gastric mucosa and laxative.
  • the ginseng ingredients of the invention are used for spleen and digestion, diarrhea, diarrhea, spleen and stomach weakness, spleen and stomach, abdominal distension, qi and spleen, and loss of appetite.
  • the invention adopts a plurality of medicine and food homologous plants (parameters) as a nutrient powder medium, and feeds a plurality of probiotics for breeding, and under the premise that the various active ingredients of the original reference ingredients are not changed,
  • the active ingredients of the drug are incorporated into the probiotics to form a high concentration of probiotic liquid containing the active ingredient, which facilitates subsequent amino acid fermentation and produces various beneficial ingredients for the human body.
  • the invention adopts various types of amino acid mixing and dry-base fermentation with high-concentration probiotic liquid, and produces a series of metabolites in the fermentation process, and the high-concentration probiotic liquid can effectively infiltrate into the comprehensive amino acid, forming favorable for New active substances in the human body;
  • the amino acid solution can fully exert various beneficial components absorbed by the human body, and can enhance the immune function of the human body and enhance the nutrient absorption capacity. Promote sleep and improve the gastrointestinal function of the human body.
  • the beverage of the invention improves the flavor of the original material product, can activate various biological activities in the human body, effectively regulates the gastrointestinal function and physiological metabolism of the human body; has good taste, can be taken for a long time, and is safe and non-toxic.
  • the equipment and materials used in the preparation process of the beverage for regulating human gastrointestinal function are as follows:
  • a beverage for regulating the function of human gastrointestinal tract comprising the following preparation steps:
  • the ginseng ingredients are pulverized separately, passed through a 100 mesh sieve, and sterilized by high temperature to obtain a ginseng powder; wherein the ginseng ingredients include: 3 g of chicken gold, 3 g of amomum, 3 g of malt, 3 g of cockroach, 3 g of atractylodes, 3 g of tangerine peel 3g lentils, 3g yellow ginseng, 3g sarcophagus;
  • Probiotics are prepared by mixing the following percentages of bacteria: Bulgarian lactic acid bacteria 12%, Streptococcus thermophilus 16%, Lactobacillus acidophilus 18%, Lactobacillus plantarum 13%, Lactobacillus casei 20% and Lactococcus 21 %;
  • an amino acid material wherein the comprehensive amino acid is mixed by the following raw materials by weight: aspartic acid 3%, threonine 3%, 3% of serine, 3% of glutamic acid, 3% of glycine, 3% of alanine, 4% of tyrosine, 4% of methionine, 3% of isoleucine, 4% of tyrosine, phenylalanine 3%, aminobutyric acid 4%, and urethane 4%, proline 4%, lysine 4%, valine 3%, histidine 4%, tryptophan 18%, arginine 5%, hydroxyproline 18%;
  • the finished product After the finished product has passed the test, it will enter the aseptic production line for quantitative packaging, and obtain a drink that can regulate the gastrointestinal function of the human body.
  • This embodiment uses a 50 degree white spirit.
  • a beverage for regulating the function of human gastrointestinal tract comprising the following preparation steps:
  • the ginseng ingredients are pulverized separately, passed through a 200 mesh sieve, and sterilized by high temperature to obtain a ginseng powder; wherein the ginseng ingredients include: 5 g of chicken inner gold, 6 g of amomum, 7 g of malt, 3 g of sputum, 7 g of atractylodes, 4 g of tangerine peel. , 6g lentils, 5g yellow ginseng, 3g sarcophagus;
  • Probiotics are prepared by mixing the following percentages of bacteria: Bulgarian lactic acid bacteria 16%, Streptococcus thermophilus 17%, Lactobacillus acidophilus 18%, Lactobacillus plantarum 19%, Lactobacillus casei 23% and Lactobacillus 7 %;
  • amino acid materials (4) Adding 52kg of synthetic amino acids to the high-concentration probiotics solution for dry fermentation for 40 hours to obtain amino acid materials; wherein the comprehensive amino acids are mixed by the following weight percentages of raw materials: aspartic acid 3%, threonine 2%, 1% serine, 2% glutamic acid, 3% glycine, 2% alanine, 4% carnitine, 3.5% methionine, 2.5% isoleucine, 4% tyrosine, phenylalanine 2%, 3% aminobutyric acid, 4% uridine, 3% valine, 4% lysine, 3% valine, 3% histidine, 22% tryptophan, 5% arginine Hydroxyproline 24%;
  • the finished product After the finished product has passed the test, it will enter the aseptic production line for quantitative packaging, and obtain a drink that can regulate the gastrointestinal function of the human body.
  • This embodiment uses a liquor of 35 degrees.
  • a beverage for regulating the function of human gastrointestinal tract comprising the following preparation steps:
  • the ginseng ingredients are pulverized separately, passed through a 200 mesh sieve, and sterilized by high temperature to obtain a ginseng powder; wherein the ginseng ingredients include: 7 g chicken inner gold, 7 g amomum, 7 g malt, 7 g glutinous rice, 7 g atractylodes, 7 g dried tangerine peel. , 7g lentils, 7g yellow ginseng, 7g sarcophagus;
  • probiotics are mixed by the following percentages of bacteria: 10% of Bulgarian lactic acid bacteria, 9% of Streptococcus thermophilus, 18% of Lactobacillus acidophilus, 19% of Lactobacillus plantarum, 23% of Lactobacillus casei and Lactobacillus twenty one%;
  • the finished product After the finished product has passed the test, it will enter the aseptic production line for quantitative packaging, and obtain a drink that can regulate the gastrointestinal function of the human body.
  • This embodiment uses a liquor of 45 degrees.
  • the acute toxicity test of the beverages obtained by the three examples of the present invention proves to be an actual non-toxic grade; the results of the sperm abnormality test and the micronucleus test indicate that there is no mutagenicity; the results of the subchronic toxicity test indicate that the growth and biochemical indexes of the animal are on the animal. , liver and kidney and other organs have no effect.
  • Acute toxicity test 60 healthy NIH mice were selected and intragastrically administered at 10g/kg for 14 days. No mice died, LD50>10g/kg, evaluated according to acute toxicity grading standards, belonging to actual non-toxic grade. .
  • Micronucleus test 55 healthy NIH mice were randomly divided into 11 groups, 5 in each group. Three doses of high, medium and low were set, and negative and positive control groups were set up. The animals were exposed to poisoning twice, 24 hours apart, and the animals were sacrificed 6 hours after the last exposure. The number of polychromatic red blood cells containing micronuclei was observed. The results are shown in Table 1. The test results showed that the three doses of high, medium and low of Example 1 were obtained. The incidence of micronuclei (MN%) was 1.8%, 1.6%, and 1.9%, respectively. The incidence of micronuclei (MN%) of high, medium, and low doses in Example 2 was 1.8%, 1.9%, and 1.6%, respectively.
  • Example 3 The incidence rates of micronuclei in the high, medium and low doses of Example 3 (MN%) were 1.8%, 1.8%, and 1.9%, respectively, and the negative and positive control groups were 1.8% and 35%, respectively. The incidence of micronuclei in each dose group was not different from that in the negative control. The sample had no significant effect on micronucleus formation and PCE/RBC ratio.
  • Subchronic toxicity test 40 healthy SD rats were randomly divided into 4 groups, 10 in each group. Three doses of high, medium and low were set, and a negative control group (water) was set up. The stomach was administered once a day for 90 days. Animal behavior, body weight, diet, morbidity and mortality were observed during the test. After the end of the experiment, histopathological examination was performed, and no significant pathological changes were found. The growth and development of the animals were normal.
  • Treatment group oral administration of the present invention, 150-260 ml orally per day (depending on age), 7 days for a course of treatment, drinking once in the morning and evening.
  • Control group Oral analgesia oral liquid was taken orally. Statistics after 3 courses of treatment. The statistical results are shown in Table 3. The test results show that the total effective rate of drinking the treatment group of the first embodiment of the present invention is 90%, and the total effective rate of drinking the treatment group of the second embodiment of the present invention is 95%. The total effective rate of the treatment group in Example 3 is as high as 100%, and the total effective rate of drinking traditional pediatric anorexia oral liquid is only 60%. It can be seen that drinking the beverage of the present invention can regulate the gastrointestinal spleen and stomach disorders of the human body, and the effect is greatly Better than traditional similar drinks.
  • the efficacy standard was formulated according to the "Diagnostic and Efficacy Standards for TCM Diseases". Clinical recovery: increased body mass, normal appetite, good spirits, reconciliation, close to normal healthy children's constitution, various symptoms disappeared; markedly effective: increased body mass, mental, appetite and other symptoms improved; improved: child body quality, Appetite and spirit have improved, but there are symptoms of malnutrition; invalid: no change in symptoms and signs.
  • 120 elderly people over 50 years old with chronic gastroenteritis were selected. There were 60 males and 60 females. The course of disease was from June to 1 year. There were no significant differences in age, gender, condition and course of disease. P>0.05). 120 elderly patients were randomly divided into four groups, three groups were the treatment group, one group was the experimental group, each group had 15 cases of male and female, and the three groups of treatment groups drank the drinks of Example 1, Example 2 and Example 3, respectively.
  • Treatment group Oral administration of the drink of the present invention, oral administration of 260 ml per day, 7 days for a course of treatment, drinking once in the morning and evening.
  • Control group Oral liquid amino acid oral solution was used. Statistics after 3 courses of treatment. The statistical results are shown in Table 4. The test results showed that the total effective rate of drinking the treatment group of Example 1 of the present invention was 96.7%, and the total effective rate of drinking the treatment group of Example 2 of the present invention was 93.3%. The total effective rate of the treatment group in Example 3 is as high as 100%, and the total effective rate of drinking traditional amino acid oral liquid is only 73.3%. It can be seen that drinking the beverage of the present invention can regulate the human stomach and stomach, and the effect of treating chronic gastroenteritis is greatly improved. Better than traditional similar drinks.
  • Example 1 Group Number of cases get well Significant effect Better invalid Always effective Treatment group (Example 1) 30 25 3 1 1 96.7% Treatment group (Example 2) 30 twenty one 5 2 2 93.3% Treatment group (Example 3) 30 twenty three 6 1 0 100% Control group 30 5 6 11 8 73.3%

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Mycology (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Non-Alcoholic Beverages (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

一种调节人体肠胃机能的饮品，将参配料粉碎后与白砂糖、白酒混均，加入纯净水和益生菌进行繁殖获得高浓度益生菌液，再将高浓度益生菌液加入综合氨基酸进行干发酵获得氨基酸料，最后将氨基酸料加纯净水、白砂糖和酵母菌进行发酵制备而获得成品；由于采用多种药食同源植物作为营养粉状培养基，喂养多种益生菌进行繁殖，在保存原有参配料各种有效成分不发生改变的前提下，将药物的有效成分融入到益生菌中，形成含有活性成分的高浓度益生菌液，有利于后续的氨基酸发酵。

Description

一种调节人体肠胃机能的饮品 技术领域
本发明属于日常生活饮品领域，涉及一种功能性饮料，尤其涉及一种含有益生菌及多种氨基酸的用于调理人体肠胃机能的饮品。
背景技术
随着社会的发展，人们对生活质量的要求日益提高，导致社会竞争日趋激烈，人们除了承受巨大的工作压力之外，还面临着家庭和生活上的压力，没时间锻炼或缺乏时间锻炼、睡眠不足、情绪经常处于紧张状态等情况已成为普遍现象，常常引起人体的神经系统、内分泌系统、免疫自主调节系统等功能性紊乱、失调，表现为精神不振、失眠、乏力、无食欲、抵抗力差等，最终引起人体病理、生理改变，尤其是人体肠胃机能失调、病变。
肠胃作为人体营养吸收、消化最重要的器官，也是常见病、多发病的器官。现代人生活节奏快，生活作息不正常、工作压力大、饮食结构不合理、不规律等情况会引起肠胃的运动和分泌失调，许多人有或轻或重的肠胃不适症状，严重的导致相应的胃肠疾病产生。
随着科技的发展，人们保健意识的加强，将食品科学与预防医学融为一体进行研究，使得食品具有特殊的保健功能是食品科学技术的发展方向。以提供营养、调节人体机能为主要作用的保健食品应运而生，其中集科技、时尚、健康、营养于一体的益生菌饮料越来越受到消费者的欢迎，具有促进消化、改善免疫、美容等功效，以提高人们的健康水平和健康状态。目前市场上含有益生菌的饮料越来越多，但大多数都是基于满足消费者对口感的需求，营养成分单一，功能保健效果不理想，加上市场上冷链不完善，导致益生菌饮料中的活菌数呈递减的趋势，在实际饮用时，很难达到理想的效果。
发明内容
本发明的目的是提供一种调节人体肠胃机能的饮品，将保健药物、氨基酸与益生菌进行有机结合，能有效地调节人体肠胃的运动和分泌，饮用方便，效果好。
为了实现上述目的，本发明的技术方案为：提供一种调节人体肠胃机能的饮品，其中，是将参配料粉碎后与白砂糖、白酒混均，接着加入纯净水和益生菌进行繁殖获得高浓度益生菌液，再将高浓度益生菌液加入综合氨基酸进行干发酵获得氨基酸料，最后将氨基酸料加纯净水、白砂糖和酵母菌进行发酵制备而获得成品；
所述参配料包括：3～7g鸡内金、3～7g砂仁、3～7g麦芽、3～7g茯苓、3～7g白术、3～7g陈皮、3～7g扁豆、3～7g黄参、3～7g石斛；
所述益生菌是由以下重量百分比的菌种混匀而成：保加利亚乳酸菌6～16％、嗜热链球菌5～17％、嗜酸乳杆菌7～18％、植物乳杆菌5～19％、干酪乳杆菌8～23％和乳酸球菌7～21％；
所述综合氨基酸是由以下重量百分比的原料混均而成：天冬氨酸1～3％、苏氨酸1～3％、丝氨酸0.8～3％、谷氨酸1～3％、甘氨酸1～3％、丙氨酸0.8～3％、腕氨酸1～4％、蛋氨酸1.4～4％、异亮氨酸0.9～3％、酪氨酸1.2～4％、苯丙氨酸1～3％、氨基丁酸0.8～4％、乌氨酸1～4％、缬氨酸1.4～4％、赖氨酸1.3～4％、脯氨酸1～3％、组氨酸1～4％、色氨酸5～23％、精氨酸1～5％、羟基脯氨酸8～25％；
所述酵母菌是由面包酵母菌和酿酒酵母菌按重量比1:1混匀而成；
上述调节人体肠胃机能的饮品的制备方法，其具体步骤如下：
(1)将参配料分别粉碎，过100～200目筛，经高温杀菌消毒，获得参配料粉；
(2)在参配料粉中加入白砂糖、白酒混匀后，获得喂养料，其中：参配料微粉、白砂糖、白酒的重量比为：2～4:2～8:1；
(3)在喂养料中加入纯净水、益生菌后进行繁殖3～8天，过滤，获得高 浓度益生菌液；其中：喂养液、纯净水、益生菌的重量比为30～50:1000～1300:1；
(4)在高浓度益生菌液中加入综合氨基酸进行干发酵20～60小时，获得氨基酸料；其中：高浓度益生菌液与综合氨基酸的重量比为1：10～20；
(5)将氨基酸料放入反应釜，加纯净水后，加热，待温度升至40～60℃，加入白砂糖，煮开后保持20～100分钟，静置降温，在24～120小时内加入酵母菌，继续分解发酵360～600小时后，获得氨基酸液即为成品，其中：氨基酸料、纯净水、白砂糖、酵母菌的重量比为30～65:2000:120～300:1；
(6)成品检测合格后进入无菌生产线进行定量包装，获得能调节人体肠胃机能的饮品。
本发明调节人体肠胃机能的饮品，具有以下的有益效果：
(1)本发明经过反复筛选配比实验，有选择的挑选鸡内金、砂仁、麦芽、茯苓、白术、陈皮、扁豆、黄参、石斛保健药物组分，并按一定的比例进行组合而成参配料，药效能产生增效作用；鸡内金可消食健胃助消化，可以促进胃液分泌，提高为胃酸度及消化力，使胃运动功能明显增强，胃排空加快。砂仁辛温行散，芳香化湿，主入脾胃，为化湿和中醒脾要药；麦芽可改善食积不消，脘腹胀痛，脾虚食少。茯苓益气健脾渗湿为君，陈皮具有促进消化、保护胃黏膜、通便。本发明的参配料用于健脾消食、对利湿、腹泻、脾胃虚弱、脾胃使和，脘腹胀满、益气健脾、食欲不振均有全面调理作用。
(2)本发明采用多种药食同源植物(参配料)为营养粉状培养基，喂养多种益生菌进行繁殖，在保存原有参配料各种有效成分不发生改变的前提下，将药物的有效成分融入到益生菌中，形成含有活性成分的高浓度益生菌液，利于后续的氨基酸发酵，产生各种对人体有益成分。
(3)本发明采用多种类型的氨基酸混合后与高浓度益生菌液进行干基发酵，在发酵过程中产生系列代谢产物，高浓度益生菌液能有效地渗入到综合氨基酸内，形成有利于人体的新活性物质；
(4)本发明将氨基酸料与酵母菌进行二次发酵后，氨基酸液能充分发挥多种被人体所吸收的有益成分，并且能增强人体免疫功能，加强营养吸收能力， 促进睡眠，改善人体肠胃功能。
(5)本发明饮品提高了原有物质产品的风味，可以激活人体内多种生物活性，有效调节人体肠胃功能和生理代谢作用；口感良好，可长期服用，服用安全无毒。
具体实施方式
下面结合实施例，对本发明的具体实施方式作进一步详细描述。以下实施例用于说明本发明，但不用来限制本发明的范围。下列实施例中未注明具体条件的实验方法,通常按照常规条件,或按照制造厂商所建议的条件。
本发明调节人体肠胃机能的饮品制备过程所使用到的设备及材料如下：
1、粉碎机；2、搅拌机；3、高压罐；4、处理水净化器；5、高压水枪；6、消毒器；7、显微镜；8、微粉机；9、净化工作台；10、产品检验器材；11、培养基；12、干燥机；13、冰箱；14、高温度罐；15、天平秤；16、反应釜；17、产品包装机；18、封盖机；19、洗瓶机；20、净化过滤器。
实施例1
一种调节人体肠胃机能的饮品，包括以下制备步骤：
(1)将参配料分别粉碎，过100目筛，经高温杀菌消毒，获得参配料粉；其中，参配料包括：3g鸡内金、3g砂仁、3g麦芽、3g茯苓、3g白术、3g陈皮、3g扁豆、3g黄参、3g石斛；
(2)在参配料粉中加入30g白砂糖、10g白酒混匀后，获得喂养料；
(3)在喂养料中加入2kg纯净水、2g益生菌后进行繁殖3天，过滤，获得高浓度益生菌液(每种菌种的个数均达3.68×109Cfu/ml以上)；其中，益生菌是由以下重量百分比的菌种混匀而成：保加利亚乳酸菌12％、嗜热链球菌16％、嗜酸乳杆菌18％、植物乳杆菌13％、干酪乳杆菌20％和乳酸球菌21％；
(4)在高浓度益生菌液中加入21kg综合氨基酸进行干发酵20小时，获得氨基酸料；其中，综合氨基酸是由以下重量百分比的原料混均而成：天冬氨酸3％、苏氨酸3％、丝氨酸3％、谷氨酸3％、甘氨酸3％、丙氨酸3％、腕氨酸4％、蛋氨酸4％、异亮氨酸3％、酪氨酸4％、苯丙氨酸3％、氨基丁酸4％、乌氨酸 4％、缬氨酸4％、赖氨酸4％、脯氨酸3％、组氨酸4％、色氨酸18％、精氨酸5％、羟基脯氨酸18％；
(5)将氨基酸料放入反应釜，加1吨纯净水后，加热，待温度升至40℃，加入60kg白砂糖，煮开后保持30分钟，静置降温，在24小时后加入500g酵母菌，继续分解发酵360小时，获得氨基酸液即为成品；其中，酵母菌是由面包酵母菌和酿酒酵母菌按重量比1:1混匀而成。
(6)成品检测合格后进入无菌生产线进行定量包装，获得能调节人体肠胃机能的饮品。
本实施例采用50度的白酒。
实施例2
一种调节人体肠胃机能的饮品，包括以下制备步骤：
(1)将参配料分别粉碎，过200目筛，经高温杀菌消毒，获得参配料粉；其中，参配料包括：5g鸡内金、6g砂仁、7g麦芽、3g茯苓、7g白术、4g陈皮、6g扁豆、5g黄参、3g石斛；
(2)在参配料粉中加入60g白砂糖、20g白酒混匀后，获得喂养料；
(3)在喂养料中加入5kg纯净水、4g益生菌后进行繁殖5天，过滤，获得高浓度益生菌液(每种菌种的个数均达3.94×109Cfu/ml以上)；其中，益生菌是由以下重量百分比的菌种混匀而成：保加利亚乳酸菌16％、嗜热链球菌17％、嗜酸乳杆菌18％、植物乳杆菌19％、干酪乳杆菌23％和乳酸球菌7％；
(4)在高浓度益生菌液中加入52kg综合氨基酸进行干发酵40小时，获得氨基酸料；其中，综合氨基酸是由以下重量百分比的原料混均而成：天冬氨酸3％、苏氨酸2％、丝氨酸1％、谷氨酸2％、甘氨酸3％、丙氨酸2％、腕氨酸4％、蛋氨酸3.5％、异亮氨酸2.5％、酪氨酸4％、苯丙氨酸2％、氨基丁酸3％、乌氨酸4％、缬氨酸3％、赖氨酸4％、脯氨酸3％、组氨酸3％、色氨酸22％、精氨酸5％、羟基脯氨酸24％；
(5)将氨基酸料放入反应釜，加3吨纯净水后，加热，待温度升至50℃，加入300kg白砂糖，煮开后保持80分钟，静置降温，在50小时后加入1.5kg酵 母菌，继续分解发酵500小时，获得氨基酸液即为成品；其中，酵母菌是由面包酵母菌和酿酒酵母菌按重量比1:1混匀而成。
(6)成品检测合格后进入无菌生产线进行定量包装，获得能调节人体肠胃机能的饮品。
本实施例采用35度的白酒。
实施例3
一种调节人体肠胃机能的饮品，包括以下制备步骤：
(1)将参配料分别粉碎，过200目筛，经高温杀菌消毒，获得参配料粉；其中，参配料包括：7g鸡内金、7g砂仁、7g麦芽、7g茯苓、7g白术、7g陈皮、7g扁豆、7g黄参、7g石斛；
(2)在参配料粉中加入75g白砂糖、25g白酒混匀后，获得喂养料；
(3)在喂养料中加入5.5kg纯净水、4g益生菌后进行繁殖8天，过滤，获得高浓度益生菌液(每种菌种的个数均达3.85×109Cfu/ml以上)；其中，益生菌是由以下重量百分比的菌种混匀而成：保加利亚乳酸菌10％、嗜热链球菌9％、嗜酸乳杆菌18％、植物乳杆菌19％、干酪乳杆菌23％和乳酸球菌21％；
(4)在高浓度益生菌液中加入84g综合氨基酸进行干发酵60小时，获得氨基酸料；其中，综合氨基酸是由以下重量百分比的原料混均而成：天冬氨酸1％、苏氨酸3％、丝氨酸3％、谷氨酸3％、甘氨酸3％、丙氨酸3％、腕氨酸4％、蛋氨酸4％、异亮氨酸3％、酪氨酸4％、苯丙氨酸3％、氨基丁酸4％、乌氨酸4％、缬氨酸1％、赖氨酸1％、脯氨酸1％、组氨酸2％、色氨酸23％、精氨酸5％、羟基脯氨酸25％；
(5)将氨基酸料放入反应釜，加4吨纯净水后，加热，待温度升至60℃，加入白砂糖，煮开后保持80分钟，静置降温，在120小时后加入2kg酵母菌，继续分解发酵600小时，获得氨基酸液即为成品；其中，酵母菌是由面包酵母菌和酿酒酵母菌按重量比1:1混匀而成；
(6)成品检测合格后进入无菌生产线进行定量包装，获得能调节人体肠胃机能的饮品。
本实施例采用45度的白酒。
试验过程：
一、毒性测定：
对本发明三个实施例获得的饮品进行急性毒性试验，证明属于实际无毒级；精子畸形试验和微核试验的结果表明没有诱变性；亚慢性毒性试验结果表明其对动物生长发育、生化指标、肝肾等器官无影响。
试验按照国家标准《食品安全性毒理学评价程序和方法》中有关的方法进行。
(1)急性毒性实验：选取健康NIH小鼠60只，按10g/kg灌胃一次，观察14天，无小鼠死亡，LD50>10g/kg，按急性毒性分级标准评价，属于实际无毒级。
(2)微核试验：选取健康NIH小鼠55只，随机分为11组，每组5只。设高、中、低三个剂量，并设阴性和阳性对照组。动物连续染毒2次，间隔24h，末次染毒后6h处死动物，观察含有微核的嗜多染红细胞数，结果见表1，试验结果表明，实施例1的高、中、低三个剂量微核发生率(MN％)分别为1.8％，1.6％，1.9％，实施例2的高、中、低三个剂量微核发生率(MN％)分别为1.8％，1.9％，1.6％，实施例3的高、中、低三个剂量微核发生率(MN％)分别为1.8％，1.8％，1.9％，阴性和阳性对照组分别为1.8％和35％。各剂量组微核发生率与阴性对照无差异，样品对微核形成及PCE/RBC比值无明显影响。
表1 小鼠骨髓微核试验结果
Figure PCTCN2017071715-appb-000001
Figure PCTCN2017071715-appb-000002
(3)精子畸形试验：选取健康NIH雄性小鼠55只，随机分为11组，每组5只。设高、中、低三个剂量，并设阴性和阳性对照组。实验动物连续灌胃5天，每天1次，染毒后第35天处死动物，取双侧附睾制片染色，每鼠计数1000个完整精子，记录畸变精子数目，结果见表2，试验结果表明，实施例1的高、中、低三个剂量精子畸形率分别为1.5％，1.3％，1.6％；实施例2的高、中、低三个剂量精子畸形率分别为1.4％，1.5％，1.6％；实施例3的高、中、低三个剂量精子畸形率分别为1.2％，1.7％，1.5％；阴性和阳性对照组分别为1.8％和25％。样品对精子无明显致畸形作用。
表2 小鼠精子畸形试验结果
Figure PCTCN2017071715-appb-000003
(4)亚慢性毒性试验：健康SD大鼠40只，随机分为4组，每组10只。设高、中、低三个剂量，并设阴性对照组(水)，每天灌胃1次，试验90天，试验期间观察动物行为、体重、饮食、发病和死亡等情况。试验结束后进行病理组织形态学检查，未发现有意义的病理改变，动物生长发育无异常。
二、临床统计试验：
1、选取胃肠功能脾胃失调(如小儿疳积)儿童80例，男40例，女40例，年龄1～6岁，病程1月至1年，男女儿童在年龄、性别、病情及病程等方面差 异均无统计学意义(P>0.05)。将80例儿童随机分为四组，三组为治疗组，一组为试验组，每组男女各10例，三组治疗组分别饮用实施例1、实施例2、实施例3的饮品。
治疗组：采用口服本发明饮品，每天口服150～260ml(服用量根据年龄而定)，7天为一个疗程，早、晚饮用一次。
对照组：采用口服市面上的小儿厌食口服液。服用3个疗程后统计结果。统计结果见表3，试验结果表明，饮用本发明实施例1的治疗组的人数总有效率为90％，饮用本发明实施例2的治疗组的人数总有效率为95％，饮用本发明实施例3的治疗组的人数总有效率高达100％，饮用传统的小儿厌食口服液的人数总有效率才60％，可以看出，饮用本发明饮品均可调节人体胃肠功能脾胃失调，效果大大优于传统类似的饮品。
疗效标准根据《中医病症诊断疗效标准》制定。临床痊愈：体质量增加，食欲正常，精神良好，二便调和，接近正常健康小儿体质，各种症状消失；显效：体质量有所增加，精神、食欲及其他症状改善；好转：儿童体质量、食欲、精神有所改善，但遗有营养不良症状；无效：症状及体征均无变化。
表3 80例儿童试验结果
组别 例数 痊愈 显效 好转 无效 总有效
治疗组(实施例1) 20 15 2 1 2 90％
治疗组(实施例2) 20 13 4 2 1 95％
治疗组(实施例3) 20 16 2 2 0 100％
对照组 20 2 6 4 8 60％
2、选取120例患有慢性肠胃炎的50岁以上的老年人，男60例，女60例，病程6月至1年，在年龄、性别、病情及病程等方面差异均无统计学意义(P>0.05)。将120例老年人随机分为四组，三组为治疗组，一组为试验组，每组男女各15例，三组治疗组分别饮用实施例1、实施例2、实施例3的饮品。
治疗组：采用口服本发明饮品，每天口服260ml，7天为一个疗程，早、晚饮用一次。
对照组：采用口服市面上的氨基酸口服液。服用3个疗程后统计结果。统计结果见表4，试验结果表明，饮用本发明实施例1的治疗组的人数总有效率为96.7％，饮用本发明实施例2的治疗组的人数总有效率为93.3％，饮用本发明实施例3的治疗组的人数总有效率高达100％，饮用传统的氨基酸口服液的人数总有效率才73.3％，可以看出，饮用本发明饮品均可调节人体肠胃，治疗慢性肠胃炎的效果大大优于传统类似的饮品。
表4 120例老年人试验结果
组别 例数 痊愈 显效 好转 无效 总有效
治疗组(实施例1) 30 25 3 1 1 96.7％
治疗组(实施例2) 30 21 5 2 2 93.3％
治疗组(实施例3) 30 23 6 1 0 100％
对照组 30 5 6 11 8 73.3％
三、临床具体案例：
1、李某，女，52岁，先天体质虚弱，免疫力低下，易感冒发烧，服用本发明饮品，每日两次，早、晚各服100ml，20天后，体质增强，免疫力明显提高，不再经常感冒发烧。
2、曾某，男，21岁，患有慢性肠胃炎，病程5个月，长期拉肚子，身体消瘦多方求医无效，服用本发明饮品，每日三次，早、中、晚各服100ml，25天后，体重增加，胃口好，也不拉肚子了。
3、王某，女，8岁，患有小儿疳积，病程一年，形体消瘦，长期腹胀，服用本发明饮品，每日三次，早、中、晚各服80ml，45天后，体重增加，肚子不胀，脸色红润。
4、张某，男，65岁，患有急性肠胃炎，病程长达三年之久，长期肚子疼痛难忍，急痛时，服用本发明饮品，每日三次，早、中、晚各服160ml，2天后， 疼痛感消失，精神好转，坚持服用两个月后，极少出现肚子疼痛的症状。
以上所揭露的仅为本发明的较佳实施例而已，当然不能以此来限定本发明之权利范围，因此依本发明权利要求所作的等同变化，仍属于本发明所涵盖的范围。

Claims (1)

  1. 一种调节人体肠胃机能的饮品，其特征在于，是将参配料粉碎后与白砂糖、白酒混均，接着加入纯净水和益生菌进行繁殖获得高浓度益生菌液，再将高浓度益生菌液加入综合氨基酸进行干发酵获得氨基酸料，最后将氨基酸料加纯净水、白砂糖和酵母菌进行发酵制备而获得成品；
    所述参配料包括：3～7g鸡内金、3～7g砂仁、3～7g麦芽、3～7g茯苓、3～7g白术、3～7g陈皮、3～7g扁豆、3～7g黄参、3～7g石斛；
    所述益生菌是由以下重量百分比的菌种混匀而成：保加利亚乳酸菌6～16％、嗜热链球菌5～17％、嗜酸乳杆菌7～18％、植物乳杆菌5～19％、干酪乳杆菌8～23％和乳酸球菌7～21％；
    所述综合氨基酸是由以下重量百分比的原料混均而成：天冬氨酸1～3％、苏氨酸1～3％、丝氨酸0.8～3％、谷氨酸1～3％、甘氨酸1～3％、丙氨酸0.8～3％、腕氨酸1～4％、蛋氨酸1.4～4％、异亮氨酸0.9～3％、酪氨酸1.2～4％、苯丙氨酸1～3％、氨基丁酸0.8～4％、乌氨酸1～4％、缬氨酸1.4～4％、赖氨酸1.3～4％、脯氨酸1～3％、组氨酸1～4％、色氨酸5～23％、精氨酸1～5％、羟基脯氨酸8～25％；
    所述酵母菌是由面包酵母菌和酿酒酵母菌按重量比1:1混匀而成；
    上述调节人体肠胃机能的饮品的制备方法，其具体步骤如下：
    (1)将参配料分别粉碎，过100～200目筛，经高温杀菌消毒，获得参配料粉；
    (2)在参配料粉中加入白砂糖、白酒混匀后，获得喂养料，其中：参配料微粉、白砂糖、白酒的重量比为：2～4:2～8:1；
    (3)在喂养料中加入纯净水、益生菌后进行繁殖3～8天，过滤，获得高浓度益生菌液；其中：喂养液、纯净水、益生菌的重量比为30～50:1000～1300:1；
    (4)在高浓度益生菌液中加入综合氨基酸进行干发酵20～60小时，获得氨基酸料；其中：高浓度益生菌液与综合氨基酸的重量比为1：10～20；
    (5)将氨基酸料放入反应釜，加纯净水后，加热，待温度升至40～60℃，加入白砂糖，煮开后保持20～100分钟，静置降温，在24～120小时内加入酵母菌，继续分解发酵360～600小时后，获得氨基酸液即为成品，其中：氨基酸料、纯净水、白砂糖、酵母菌的重量比为30～65:2000:120～300:1；
    (6)成品检测合格后进入无菌生产线进行定量包装，获得能调节人体肠胃机能的饮品。
PCT/CN2017/071715 2017-01-19 2017-01-19 一种调节人体肠胃机能的饮品 WO2018133007A1 (zh)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PCT/CN2017/071715 WO2018133007A1 (zh) 2017-01-19 2017-01-19 一种调节人体肠胃机能的饮品
CN201780009884.9A CN108882730B (zh) 2017-01-19 2017-01-19 一种调节人体肠胃机能的饮品

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2017/071715 WO2018133007A1 (zh) 2017-01-19 2017-01-19 一种调节人体肠胃机能的饮品

Publications (1)

Publication Number Publication Date
WO2018133007A1 true WO2018133007A1 (zh) 2018-07-26

Family

ID=62907530

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2017/071715 WO2018133007A1 (zh) 2017-01-19 2017-01-19 一种调节人体肠胃机能的饮品

Country Status (2)

Country Link
CN (1) CN108882730B (zh)
WO (1) WO2018133007A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111149962A (zh) * 2020-01-20 2020-05-15 河北天善生物技术有限公司 一种功能型饮料及其制备方法
CN112438404A (zh) * 2020-11-25 2021-03-05 兰州大学 一种黄参多糖的应用
CN113331326A (zh) * 2021-05-25 2021-09-03 晏龙国科(山东)生命科技有限公司 一种中药益生菌复合饮品及其制备方法
CN113729222A (zh) * 2020-05-29 2021-12-03 李永川 一种儿童专用的含鸡内金的食品或保健食品及其制备方法

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113100290B (zh) * 2021-05-24 2023-03-28 宁波大学 一种复合发酵菌剂在制备发酵乳中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507808A (zh) * 2002-12-13 2004-06-30 韩全文 牛蒡复合多菌种发酵功能型饮料
CN102727819A (zh) * 2012-07-05 2012-10-17 陈光明 治疗消化系统疾病的保康灵多元益生素口服液及制备方法
CN102934809A (zh) * 2012-12-10 2013-02-20 济南大学 益生菌发酵中药制剂制备的组合物及其制备方法和应用
CN103027231A (zh) * 2013-01-01 2013-04-10 蒋常德 一种复合益生菌发酵中草药活性保健液及其制备方法
CN103083606A (zh) * 2012-12-30 2013-05-08 周建设 一种康复肠胃的三次生物发酵中草药口服液及其制法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS57159494A (en) * 1981-03-30 1982-10-01 Takeshi Yanagisawa Secondary fermentation product of natural polysaccharide and method of using the same
JPS60118173A (ja) * 1983-11-28 1985-06-25 Kazuji Fukunaga 加工食品の変質防止法
CN1327887C (zh) * 2003-01-21 2007-07-25 贵州本草堂药业有限公司 一种治疗脾虚食滞引起的小儿厌食病症的中成药
CN102028197B (zh) * 2010-05-21 2014-04-09 中国人民解放军第三军医大学第一附属医院 具有调节肠道菌群失调和增强免疫的功能营养剂及其制备方法
JP5186038B2 (ja) * 2011-05-31 2013-04-17 サントリーホールディングス株式会社 飲料組成物
KR20130002613A (ko) * 2011-06-29 2013-01-08 플로바프 주식회사 허브티백과 누룩산식초를 이용한 음료 및 그 제조방법
JP6266212B2 (ja) * 2013-02-04 2018-01-24 サッポロホールディングス株式会社 固体状豆乳発酵物及びその製造方法
CN104223220A (zh) * 2013-06-10 2014-12-24 张国武 乳酸决明子饮料
US20150064310A1 (en) * 2013-09-04 2015-03-05 Darren Thompson Endurance sports drink utilizing tapioca starch
CN104082724A (zh) * 2014-06-10 2014-10-08 胡安然 一种胃癌患者食用的微生态特殊膳食
CN105146520B (zh) * 2015-09-25 2018-03-30 西藏藏真堂藏药产业有限公司 一种余甘子酵素及其制备方法
CN105249109A (zh) * 2015-11-04 2016-01-20 湖北金鹰生物科技有限公司 一种改善儿童胃肠功能，富含复合益生菌植物酵素饮品的制备方法
CN105456900A (zh) * 2016-01-08 2016-04-06 李丽芬 一种治疗小儿厌食症的中药配方
CN105795287A (zh) * 2016-03-24 2016-07-27 陕西思尔生物科技有限公司 一种针对不同人群营养补充的发酵型饮料及其制备方法
CN107821896A (zh) * 2017-12-05 2018-03-23 合肥海昭生物科技有限公司 一种活体复合益生菌饮品

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1507808A (zh) * 2002-12-13 2004-06-30 韩全文 牛蒡复合多菌种发酵功能型饮料
CN102727819A (zh) * 2012-07-05 2012-10-17 陈光明 治疗消化系统疾病的保康灵多元益生素口服液及制备方法
CN102934809A (zh) * 2012-12-10 2013-02-20 济南大学 益生菌发酵中药制剂制备的组合物及其制备方法和应用
CN103083606A (zh) * 2012-12-30 2013-05-08 周建设 一种康复肠胃的三次生物发酵中草药口服液及其制法
CN103027231A (zh) * 2013-01-01 2013-04-10 蒋常德 一种复合益生菌发酵中草药活性保健液及其制备方法

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111149962A (zh) * 2020-01-20 2020-05-15 河北天善生物技术有限公司 一种功能型饮料及其制备方法
CN113729222A (zh) * 2020-05-29 2021-12-03 李永川 一种儿童专用的含鸡内金的食品或保健食品及其制备方法
CN112438404A (zh) * 2020-11-25 2021-03-05 兰州大学 一种黄参多糖的应用
CN112438404B (zh) * 2020-11-25 2023-08-01 兰州大学 一种黄参多糖的应用
CN113331326A (zh) * 2021-05-25 2021-09-03 晏龙国科(山东)生命科技有限公司 一种中药益生菌复合饮品及其制备方法

Also Published As

Publication number Publication date
CN108882730B (zh) 2021-10-01
CN108882730A (zh) 2018-11-23

Similar Documents

Publication Publication Date Title
CN106562162B (zh) 一种海棠果益生菌发酵饮品及其制备方法
US9950024B2 (en) Traditional Chinese medicine composition and the use thereof
WO2018133007A1 (zh) 一种调节人体肠胃机能的饮品
WO2013127146A1 (zh) 一种能够缓解铅毒性的植物乳杆菌及其用途
CN108968037A (zh) 老年痴呆症全营养配方食品
CN102077866A (zh) 螺旋藻营养酸奶的制备方法
WO2020118576A1 (zh) 胚芽乳酸杆菌twk10在制备抗运动后发炎或降体脂组合物的用途
CN101244089B (zh) 嗜酸乳杆菌/粪肠球菌培养基、制剂及其工艺
CN103798494B (zh) 健胃益脾红茶菌山楂糕及其制作方法
CN107334156A (zh) 催乳全营养配方食品
CN110692884A (zh) 一种辅助降四高的益生菌保健饮料
CN106578773A (zh) 一种新型解酒饮料及其制备方法
CN108936607A (zh) 慢性阻塞性肺疾病全营养配方食品
KR101076223B1 (ko) 한약재 발효물을 유효성분으로 포함한 비만 또는 고지혈증의 예방 및 치료용 조성물
CN102919956A (zh) 调理人体消化系统的营养液及其制备方法
JP5329307B2 (ja) 抗アレルギー組成物
CN113208077A (zh) 一种益生菌枸杞醋果冻的制备方法
CN101731434B (zh) 一种含有蔓越莓的冷冻饮品
CN101878814B (zh) 阿胶小肽红枣酸奶的生产方法
CN103798667B (zh) 菌茶红枣山楂糕及其制作方法
CN106070837A (zh) 普洱茶保健饮品及其制备方法
CN108185433A (zh) 具有润肠通便和安眠作用的保健配方与制备方法及应用
CN106901107A (zh) 一种肉灵芝活性菌发酵饮料及其制备方法
CN115702655A (zh) 辅助降血脂和降血压的中老年调制羊奶粉及制备方法
CN110859259A (zh) 一种玉竹饮料及其制备方法

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 17892496

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 17892496

Country of ref document: EP

Kind code of ref document: A1